EvogeneEVGN -2.31%34 FCF Yield % is -276.64 as of Jun. 28, 2026. GuruFocus rates EVGN with a GF Score™ of 34/100 and a GF Value™ of $0.43 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, Evogene ranks worse than 96.82% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Evogene's Trailing 12-Month Free Cash Flow is $-13.64 Mil, and Market Cap is $4.90 Mil. Therefore, Evogene's FCF Yield % for today is -276.64%.
The historical rank and industry rank for Evogene's FCF Yield % or its related term are showing as below:
EVGN'
s FCF Yield % Range Over the Past 10 Years
Min: -276.64 Med: -38.13 Max: -5.34
Current: -276.64
During the past 13 years, the highest FCF Yield % of Evogene was -5.34%. The lowest was -276.64%. And the median was -38.13%.
EVGN's FCF Yield % is ranked worse than 96.82% of 1416
companies
in the Biotechnology industry
Industry Median: -9.62
vs EVGN: -276.64
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Evogene FCF Yield % Related Terms
Evogene FCF Yield % Historical Data
* Premium members only.
The historical data trend for Evogene's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evogene's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evogene FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evogene's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Evogene's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evogene (EVGN) has a FCF Yield % of -276.64 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Evogene and its competitors. According to the industry distribution chart, Evogene ranks #1371 out of 1416 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Evogene's FCF Yield % too high?
Evogene's current FCF Yield % is -276.64. Based on the distribution chart, Evogene ranks #1371 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evogene has a GF Score™ of 34/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Evogene's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Evogene ranks #1371 out of 1416 companies for FCF Yield %. This places Evogene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Evogene and its competitors. Evogene's current FCF Yield % is -276.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evogene stock overvalued right now?
Based on GuruFocus' analysis, Evogene (EVGN) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.43, compared to a current price of $0.39 — trading 9.6% below its estimated fair value. The current FCF Yield % is -276.64. Evogene's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Evogene (EVGN), the current FCF Yield % is -276.64 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evogene (EVGN) Overvalued in 2026?
Based on GuruFocus' analysis, Evogene stock appears to be undervalued.
The current stock price of $0.39 is trading 9.6% below its estimated GF Value™ of $0.43.
GuruFocus considers Evogene to be Modestly Undervalued.
Key valuation signals for EVGN:
FCF Yield %: -276.64
GF Value™: $0.43 vs. price of $0.39 (9.6% below fair value)
No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
34GF Score
Get the complete analysis for EVGN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVGN has been successfully added to your 
